Research programme: apoptosis stimulants - Novartis
Alternative Names: LBW242Latest Information Update: 22 May 2012
At a glance
- Originator Novartis
- Class Oligopeptides; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 May 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
- 19 Nov 2009 Preclinical pharmacodynamics data presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 27 Nov 2008 Preclinical development is ongoing in USA